BRADLEY, Ill. -- Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move that will bring end-to-end plasma processing into the U.S.

Illinois Gov. JB Pritzker on Monday announced a $1.5 billion investment from biotherapeutics company CSL for a new plasma therapy manufacturing plant in Kanakee. CSL will expand its current footprint ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

C SL has broken ground for an expansion of its state-of-the-art manufacturing facility in Kankakee, Illinois. The newly expanded facility will substantially increase the global biopharma company’s ...

New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies ...

(The Center Square) – A global biopharmaceutical company has announced it will invest $1.5 billion for a new manufacturing facility in Bradley, but the taxpayer cost of the project is unknown. On ...

Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection. Australia-based CSL picked ...

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

SYDNEY--Shares of pharmaceutical company CSL fell early Wednesday as investors react to the sudden departure of chief executive Paul McKenzie and an 80% fall in first-half net profit. The stock was ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...

SYDNEY--Australia-based pharmaceutical company CSL said that Chief Executive Paul McKenzie will retire after a three-year tenure. CSL said that Gordon Naylor, a highly experienced former CSL senior ...